Renaissance Technologies LLC Buys 65,800 Shares of AtriCure, Inc. (NASDAQ:ATRC)

Renaissance Technologies LLC lifted its holdings in AtriCure, Inc. (NASDAQ:ATRC - Free Report) by 67.1% during the 4th quarter, according to its most recent filing with the Securities & Exchange Commission. The firm owned 163,900 shares of the medical device company's stock after purchasing an additional 65,800 shares during the period. Renaissance Technologies LLC owned about 0.34% of AtriCure worth $5,009,000 at the end of the most recent reporting period.

A number of other institutional investors and hedge funds also recently made changes to their positions in ATRC. Heck Capital Advisors LLC bought a new position in AtriCure in the fourth quarter worth approximately $60,000. Venturi Wealth Management LLC raised its holdings in AtriCure by 1,337.6% in the 4th quarter. Venturi Wealth Management LLC now owns 2,257 shares of the medical device company's stock worth $69,000 after purchasing an additional 2,100 shares during the period. KBC Group NV lifted its position in AtriCure by 65.3% during the fourth quarter. KBC Group NV now owns 2,360 shares of the medical device company's stock valued at $72,000 after purchasing an additional 932 shares in the last quarter. R Squared Ltd bought a new stake in AtriCure during the fourth quarter valued at about $89,000. Finally, AlphaQuest LLC increased its position in AtriCure by 855.1% in the fourth quarter. AlphaQuest LLC now owns 5,062 shares of the medical device company's stock worth $155,000 after buying an additional 4,532 shares in the last quarter. Hedge funds and other institutional investors own 99.11% of the company's stock.

Insider Buying and Selling at AtriCure

In related news, Director Karen Prange sold 6,100 shares of the firm's stock in a transaction on Wednesday, March 5th. The shares were sold at an average price of $38.12, for a total value of $232,532.00. Following the completion of the transaction, the director now directly owns 17,828 shares of the company's stock, valued at approximately $679,603.36. This trade represents a 25.49 % decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which can be accessed through this hyperlink. 3.20% of the stock is currently owned by company insiders.

AtriCure Price Performance

Shares of ATRC stock traded up $1.27 during trading hours on Thursday, hitting $33.76. The stock had a trading volume of 306,457 shares, compared to its average volume of 579,491. The company has a debt-to-equity ratio of 0.13, a current ratio of 3.65 and a quick ratio of 2.62. The stock has a market capitalization of $1.65 billion, a price-to-earnings ratio of -35.54 and a beta of 1.65. AtriCure, Inc. has a one year low of $18.94 and a one year high of $43.11. The stock's 50-day moving average price is $34.56 and its two-hundred day moving average price is $34.46.

Analyst Ratings Changes

A number of research analysts recently issued reports on ATRC shares. JMP Securities reiterated a "market outperform" rating and set a $60.00 price objective on shares of AtriCure in a research note on Monday, February 10th. Piper Sandler upped their price target on shares of AtriCure from $40.00 to $50.00 and gave the stock an "overweight" rating in a research report on Thursday, February 13th. Stifel Nicolaus raised their price objective on shares of AtriCure from $36.00 to $48.00 and gave the company a "buy" rating in a research report on Thursday, February 13th. Canaccord Genuity Group dropped their target price on shares of AtriCure from $66.00 to $52.00 and set a "buy" rating for the company in a report on Friday, March 28th. Finally, Needham & Company LLC reissued a "buy" rating and set a $51.00 price target on shares of AtriCure in a report on Thursday, March 27th. One investment analyst has rated the stock with a hold rating and nine have issued a buy rating to the company. According to data from MarketBeat.com, AtriCure currently has a consensus rating of "Moderate Buy" and a consensus price target of $49.44.

AtriCure Company Profile

AtriCure, Inc develops, manufactures, and sells devices for surgical ablation of cardiac tissue, exclusion of the left atrial appendage, and temporarily blocking pain by ablating peripheral nerves to medical centers in the United States, Europe, the Asia-Pacific, and internationally. The company offers Isolator Synergy Clamps, single-use disposable radio frequency products; multifunctional pens and linear ablation devices, such as the MAX Pen device that enables surgeons to evaluate cardiac arrhythmias, perform temporary cardiac pacing, sensing, and stimulation, and ablate cardiac tissue with the same device; and the Coolrail device, which enables users to make longer linear lines of ablation.